The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1611
ISSUE 1611
November 16, 2020
Issue 1611
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
In Brief: Hydrochlorothiazide and Skin Cancer
November 16, 2020 (Issue: 1611)
The FDA has required the addition of information about
an increased risk of nonmelanoma skin cancer (basal
cell carcinoma [BCC] and squamous cell carcinoma
[SCC]) to the labels of products containing the diuretic
hydrochlorothiazide.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.